Effect of bovine lactoferrin on recurrent urinary tract infections: in vitro and in vivo evidences.
Bovine lactoferrin
Escherichia coli CFT073
Recurrent cystitis
UPEC strains
UTIs
Journal
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
ISSN: 1572-8773
Titre abrégé: Biometals
Pays: Netherlands
ID NLM: 9208478
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
08
04
2022
accepted:
09
06
2022
medline:
15
5
2023
pubmed:
30
6
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
Uropathogenic Escherichia coli (UPEC) strains are the primary cause of urinary tract infections (UTIs). UPEC strains are able to invade, multiply and persisting in host cells. Therefore, UPEC strains are associated to recurrent UTIs requiring long-term antibiotic therapy. However, this therapy is suboptimal due to the increase of multidrug-resistant UPEC. The use of non-antibiotic treatments for managing UTIs is required. Among these, bovine lactoferrin (bLf), a multifunctional cationic glycoprotein, could be a promising tool because inhibits the entry into the host cells of several intracellular bacteria. Here, we demonstrate that 100 μg/ml bLf hinders the invasion of 2.0 ± 0.5 × 10
Identifiants
pubmed: 35768747
doi: 10.1007/s10534-022-00409-1
pii: 10.1007/s10534-022-00409-1
doi:
Substances chimiques
Lactoferrin
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
491-507Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ajello M, Greco R, Giansanti F, Massucci MT, Antonini G, Valenti P (2002) Anti-invasive activity of bovine lactoferrin towards group A streptococci. Biochem Cell Biol 80:119–124. https://doi.org/10.1139/o01-211
doi: 10.1139/o01-211
pubmed: 11908635
Al-Badr A, Al-Shaikh G (2013) Recurrent urinary tract infections management in women: a review. Sultan Qaboos Univ Med J 13:359–367
doi: 10.12816/0003256
pubmed: 23984019
pmcid: 3749018
Alugupalli KR, Kalfas S (1997) Characterization of the lactoferrin-dependent inhibition of the adhesion of Actinobacilllus Actinomycetemcomitans, Prevotella Intermedia and Prevotella Nigrescens to fibroblasts and to a reconstituted basement membrane. APMIS 105:680–688. https://doi.org/10.1111/j.1699-0463.1997.tb05071.x
doi: 10.1111/j.1699-0463.1997.tb05071.x
pubmed: 9350211
Antonini G, Catania MR, Greco R, Longhi C, Pisciotta MG, Seganti L, Valenti P (1997) Anti-invasive activity of bovine lactoferrin against listeria monocytogenes. J Food Prot 60(3):267–271. https://doi.org/10.4315/0362-028X-60.3.267
doi: 10.4315/0362-028X-60.3.267
pubmed: 31195489
Appelmelk BJ, An YQ, Geerts M, Thijs BG, de Boer HA, MacLaren DM, de Graaff J, Nuijens JH (1994) Lactoferrin is a lipid A-binding protein. Infect Immun 62(6):2628–2632. https://doi.org/10.1128/iai.62.6.2628-2632.1994
doi: 10.1128/iai.62.6.2628-2632.1994
pubmed: 8188389
pmcid: 186557
Arao S, Matsuura S, Nonomura M, Miki K, Kabasawa K, Nakanishi H (1999) Measurement of urinary lactoferrin as a marker of urinary tract infection. J Clin Microbiol 37(3):553–557. https://doi.org/10.1128/JCM.37.3.553-557.1999
doi: 10.1128/JCM.37.3.553-557.1999
pubmed: 9986811
pmcid: 84465
Ashida K, Sasaki H, Sasaki YA, Loönnerdal B (2004) Cellular internalization of lactoferrin in intestinal epithelial cells. Biometals 17:311–315. https://doi.org/10.1023/b:biom.0000027710.13543.3f
doi: 10.1023/b:biom.0000027710.13543.3f
pubmed: 15222483
Bauckman KA, Matsuda R, Higgins CB, DeBosch BJ, Wang C, Mysorekar IU (2019) Dietary restriction of iron availability attenuates UPEC pathogenesis in a mouse model of urinary tract infection. Am J Physiol Renal Physiol 316(5):F814–F822. https://doi.org/10.1152/ajprenal.00133.2018
doi: 10.1152/ajprenal.00133.2018
pubmed: 30724105
pmcid: 6580250
Bjerrum L, Gahrn-Hansen B, Grinsted P (2009) Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial. Scand J Prim Health Care 2(1):6–11. https://doi.org/10.1080/02813430802535312
doi: 10.1080/02813430802535312
Blango MG, Mulvey MA (2010) Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54:1855–1863. https://doi.org/10.1128/AAC.00014-10
doi: 10.1128/AAC.00014-10
pubmed: 20231390
pmcid: 2863638
Bonkat G, Pickard R, Bartoletti R, Cai T, Geerlings SE, Köves B, Schubert S, Pilatz A, Veeratterapillay R, Wagenlehner F (2022) European Association of urology guidelines on urological infections. EAU Guidelines edn. Presented at the EAU annual congress Amsterdam, the Netherlands 2022. ISBN 978-94-92671-16-5. http://uroweb.org/guideline/urological-infections . Accessed 06 Apr 2022.
Brandenburg K, Jürgens G, Müller M, Fukuoka S, Koch MHJ (2001) Biophysical characterization of lipopolysaccharide and lipid a inactivation by lactoferrin. Biol Chem 382:1215–1225. https://doi.org/10.1515/BC.2001.152
doi: 10.1515/BC.2001.152
pubmed: 11592403
Chen L, Xiong Z, Sun L, Yang J, Jin Q (2012) VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors. Nucleic Acids Res 40:D641–D645. https://doi.org/10.1093/nar/gkr989
doi: 10.1093/nar/gkr989
pubmed: 22067448
Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB (2013) Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 26(4):822–880. https://doi.org/10.1128/CMR.00022-13
doi: 10.1128/CMR.00022-13
pubmed: 24092857
pmcid: 3811233
Cutone A, Rosa L, Lepanto MS, Scotti MJ, Berlutti F, Bonaccorsi di Patti MC, Musci G, Valenti P (2017) Lactoferrin efficiently counteracts the inflammation-induced changes of the iron homeostasis system in macrophages. Front Immunol 8:705. https://doi.org/10.3389/fimmu.2017.00705
doi: 10.3389/fimmu.2017.00705
pubmed: 28663751
pmcid: 5471297
Cutone A, Lepanto MS, Rosa L, Scotti MJ, Rossi A, Ranucci S, De Fino I, Bragonzi A, Valenti P, Musci G, Berlutti F (2019) Aerosolized bovine lactoferrin counteracts infection, inflammation and iron dysbalance in a cystic fibrosis mouse model of pseudomonas aeruginosa chronic lung infection. Int J Mol Sci 20(9):2128. https://doi.org/10.3390/ijms20092128
doi: 10.3390/ijms20092128
pubmed: 31052156
pmcid: 6540064
Diarra MS, Petitclerc D, Deschenes E, Lessard N, Grondin G, Talbot BG, Lacasse P (2003) Lactoferrin against Staphylococcus aureus mastitis. lactoferrin alone or in combination with penicillin G on bovine polymorphonuclear function and mammary epithelial cells colonisation by Staphylococcus aureus. Vet Immunol Immunopathol 95:33–42. https://doi.org/10.1016/s0165-2427(03)00098-9
doi: 10.1016/s0165-2427(03)00098-9
pubmed: 12969634
Di Biase AM, Tinari A, Pietrantoni A, Antonini G, Valenti P, Conte MP, Superti F (2004) Effect of bovine lactoferricin on enteropathogenic Yersinia adhesion and invasion in HEp-2 cells. J Med Microbiol 53:407–412. https://doi.org/10.1099/jmm.0.05410-0
doi: 10.1099/jmm.0.05410-0
pubmed: 15096550
Elass E, Masson M, Mazurier J, Legrand D (2002) Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan binding ability of interleukin-8 in human endothelial cells. Infect Immun 70:1860–1866. https://doi.org/10.1128/IAI.70.4.1860-1866.2002
doi: 10.1128/IAI.70.4.1860-1866.2002
pubmed: 11895948
pmcid: 127826
European Food Safety Authority (2012) Scientific opinion on bovine lactoferrin. EFSA J 10:2701. https://doi.org/10.2903/j.efsa.2012.2701
doi: 10.2903/j.efsa.2012.2701
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269–284. https://doi.org/10.1038/nrmicro3432
doi: 10.1038/nrmicro3432
pubmed: 25853778
pmcid: 4457377
Foxman B (2003) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 49:53–70. https://doi.org/10.1067/mda.2003.7
doi: 10.1067/mda.2003.7
pubmed: 12601337
Foxman B (2014) Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28:1–13. https://doi.org/10.1016/j.idc.2013.09.003
doi: 10.1016/j.idc.2013.09.003
pubmed: 24484571
Frioni A, Conte MP, Cutone A, Longhi C, Musci G, di Patti MC, Natalizi T, Marazzato M, Lepanto MS, Puddu P, Paesano R et al (2014) Lactoferrin differently modulates the inflammatory response in epithelial models mimicking human inflammatory and infectious diseases. Biometals 27(5):843–856. https://doi.org/10.1007/s10534-014-9740-9
doi: 10.1007/s10534-014-9740-9
pubmed: 24770943
Guglietta A (2017) Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiol 12:239–246. https://doi.org/10.2217/fmb-2016-0145
doi: 10.2217/fmb-2016-0145
pubmed: 28262045
Gupta K, Hooton TM, Stamm WE (2001) Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135(1):41–50. https://doi.org/10.7326/0003-4819-135-1-200107030-00012
doi: 10.7326/0003-4819-135-1-200107030-00012
pubmed: 11434731
Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW (2012) Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 55(8):3945–3959. https://doi.org/10.1021/jm300165m
doi: 10.1021/jm300165m
pubmed: 22449031
pmcid: 3375398
Harding GK, Ronald AR (1994) The management of urinary infections: what have we learned in the past decade? Int J Antimicrob Agents 4:83–88. https://doi.org/10.1016/0924-8579(94)90038-8
doi: 10.1016/0924-8579(94)90038-8
pubmed: 18611593
Hickling DR, Nitti VW (2013) Management of recurrent urinary tract infections in healthy adult women. Rev Urol 15:41–48. https://doi.org/10.3909/riu0566
doi: 10.3909/riu0566
pubmed: 24082842
pmcid: 3784967
Hu Y, Meng X, Zhang F, Xiang Y, Wang J (2021) The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg Microbes Infect 10(1):317–330. https://doi.org/10.1080/22221751.2021.1888660
doi: 10.1080/22221751.2021.1888660
pubmed: 33560940
pmcid: 7919907
Jepson RG, Williams G, Craig JC (2012) Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 10:CD001321. https://doi.org/10.1002/14651858.CD001321.pub5
doi: 10.1002/14651858.CD001321.pub5
pubmed: 23076891
Johnson JR (1991) Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 4:80–128. https://doi.org/10.1128/CMR.4.1.80
doi: 10.1128/CMR.4.1.80
pubmed: 1672263
pmcid: 358180
Johnson JR, Russo TA (2002) Extraintestinal pathogenic Escherichia coli: “the other bad E. coli". J Lab Clin Med 139(3):155–162. https://doi.org/10.1067/mlc.2002.121550
doi: 10.1067/mlc.2002.121550
pubmed: 11944026
Johnson JR, Russo TA (2018) Acute pyelonephritis in adults. N Engl J Med 378(1):48–59. https://doi.org/10.1056/nejmcp1702758
doi: 10.1056/nejmcp1702758
pubmed: 29298155
Josephs-Spaulding J, Krogh TJ, Rettig HC, Lyng M, Chkonia M, Waschina S, Graspeuntner S, Rupp J, Møller-Jensen J, Kaleta C (2021) Recurrent urinary tract infections: unraveling the complicated environment of uncomplicated rUTIs. Front Cell Infect Microbiol 11:562525. https://doi.org/10.3389/fcimb.2021.562525
doi: 10.3389/fcimb.2021.562525
pubmed: 34368008
pmcid: 8340884
Juthani-Mehta M, Van Ness PH, Bianco L, Rink A, Rubeck S, Ginter S, Argraves S, Charpentier P, Acampora D, Trentalange M, Quagliarello V, Peduzzi P (2016) Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: a randomized clinical trial. JAMA 316(18):1879–1887. https://doi.org/10.1001/jama.2016.16141
doi: 10.1001/jama.2016.16141
pubmed: 27787564
pmcid: 5300771
Kawasaki Y, Tazume S, Shimizu K, Matsuzawa H, Dosako S, Isoda H, Tsukiji M, Fujimura R, Muranaka Y, Isihida H (2000) Inhibitory effects of bovine lactoferrin on the adherence of enterotoxigenic Escherichia Coli to host cells. Biosci Biotech Biochem 64:348–354. https://doi.org/10.1271/bbb.64.348
doi: 10.1271/bbb.64.348
Kim CW, Lee TH, Park KH, Choi SY, Kim J (2012) Human lactoferrin suppresses TNF-α-induced intercellular adhesion molecule-1 expression via competition with NF-kB in endothelial cells. FEBS Lett 586:229–234. https://doi.org/10.1016/j.febslet.2011.12.011
doi: 10.1016/j.febslet.2011.12.011
pubmed: 22226679
Kıraç FS (2013) Is ethics approval necessary for all trials? A clear but not certain process. Mol Imaging Radionucl Ther 22:73–75. https://doi.org/10.4274/Mirt.80664
doi: 10.4274/Mirt.80664
pubmed: 24416621
pmcid: 3888015
Kӧhler CD, Dobrindt U (2011) What defines extraintestinal pathogenic Escherichia coli? Int J Med Microbiol 301:642–647. https://doi.org/10.1016/j.ijmm.2011.09.006
doi: 10.1016/j.ijmm.2011.09.006
Kolman KB (2019) Cystitis and pyelonephritis: diagnosis, treatment, and prevention. Prim Care 46(2):191–202. https://doi.org/10.1016/j.pop.2019.01.001
doi: 10.1016/j.pop.2019.01.001
pubmed: 31030820
Lepanto MS, Rosa L, Cutone A, Conte MP, Paesano R, Valenti P (2018) Efficacy of lactoferrin oral administration in the treatment of anemia and anemia of inflammation in pregnant and non-pregnant women: an interventional study. Front Immunol 9:2123. https://doi.org/10.3389/fimmu.2018.02123
doi: 10.3389/fimmu.2018.02123
pubmed: 30298070
pmcid: 6160582
Lepanto MS, Rosa L, Paesano R, Valenti P, Cutone A (2019a) Lactoferrin in aseptic and septic inflammation. Molecules 3:24. https://doi.org/10.3390/molecules24071323
doi: 10.3390/molecules24071323
Lepanto MS, Rosa L, Cutone A, Scotti MJ, Conte AL, Marazzato M, Zagaglia C, Longhi C, Berlutti F, Musci G, Valenti P, Conte MP (2019b) Bovine lactoferrin pre-treatment induces intracellular killing of AIEC LF82 and reduces bacteria-induced DNA damage in differentiated human enterocytes. Int J Mol Sci 20(22):5666. https://doi.org/10.3390/ijms20225666
doi: 10.3390/ijms20225666
pubmed: 31726759
pmcid: 6888356
Longhi C, Conte MP, Seganti L, Polidoro M, Alfsen A, Valenti P (1993) Influence of lactoferrin on the entry process of Escherichia Coli HB101(PRI203) in HeLa cells. Med Microbiol Immunol 182(1):25–35. https://doi.org/10.1007/BF00195948
doi: 10.1007/BF00195948
pubmed: 8497210
Lu J, Francis JD, Guevara MA, Moore RE, Chambers SA, Doster RS, Eastman AJ, Rogers LM, Noble KN, Manning SD, Damo SM, Aronoff DM, Townsend SD, Gaddy JA (2021) Antibacterial and anti-biofilm activity of the human breast milk glycoprotein lactoferrin against group B Streptococcus. ChemBioChem 22(12):2124–2133. https://doi.org/10.1002/cbic.202100016
doi: 10.1002/cbic.202100016
pubmed: 33755306
pmcid: 8254657
Minardi D, d’Anzeo G, Cantoro D, Conti A, Muzzonigro G (2011) Urinary tract infections in women: etiology and treatment options. Int J Gen Med 4:333–343. https://doi.org/10.2147/IJGM.S11767
doi: 10.2147/IJGM.S11767
pubmed: 21674026
pmcid: 3108201
Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, Infectious Diseases Society of America, American Society of Nephrology, American Geriatric Society (2005) Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 40:643–654. https://doi.org/10.1086/427507
doi: 10.1086/427507
pubmed: 15714408
O’Brien VP, Hannan TJ, Schaeffer AJ, Hultgren SJ (2015) Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Curr Opin Infect Dis 28:97–105. https://doi.org/10.1097/QCO.0000000000000130
doi: 10.1097/QCO.0000000000000130
pubmed: 25517222
pmcid: 4365976
O’Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ (2016) Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiol Spectr. https://doi.org/10.1128/microbiolspec.UTI-0013-2012
doi: 10.1128/microbiolspec.UTI-0013-2012
pubmed: 26999391
Paesano R, Natalizi T, Berlutti F, Valenti P (2012) Body iron delocalization: the serious drawback in iron disorders in both developing and developed countries. Pathog Glob Health 106:200–216. https://doi.org/10.1179/2047773212Y.0000000043
doi: 10.1179/2047773212Y.0000000043
pubmed: 23265420
pmcid: 4001586
Patras KA, Ha AD, Rooholfada E, Olson J, Ramachandra Rao SP, Lin AE, Nizet V (2019) Augmentation of urinary lactoferrin enhances host innate immune clearance of uropathogenic Escherichia coli. J Innate Immun 11(6):481–495. https://doi.org/10.1159/000499342
doi: 10.1159/000499342
pubmed: 31055580
pmcid: 6758950
Phé V, Pakzad M, Haslam C, Gonzales G, Curtis C, Porter B, Chataway J, Panicker JN (2017) Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol Urodyn 36:1770–1775. https://doi.org/10.1002/nau.23173
doi: 10.1002/nau.23173
pubmed: 27813195
Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P (2017) Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis. Int J Mol Sci 18:1985. https://doi.org/10.3390/ijms18091985
doi: 10.3390/ijms18091985
pubmed: 28914813
pmcid: 5618634
Rosa L, Lepanto MS, Cutone A, Siciliano RA, Paesano R, Costi R, Musci G, Valenti P (2020) Influence of oral administration mode on the efficacy of commercial bovine Lactoferrin against iron and inflammatory homeostasis disorders. Biometals 33(2–3):159–168. https://doi.org/10.1007/s10534-020-00236-2
doi: 10.1007/s10534-020-00236-2
pubmed: 32274616
Rossi P, Giansanti F, Boffi A, Ajello M, Valenti P, Chiancone E, Antonini G (2002) Ca
doi: 10.1139/o01-209
pubmed: 11908642
Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE (2005) Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 142:20–27. https://doi.org/10.7326/0003-4819-142-1-200501040-00008
doi: 10.7326/0003-4819-142-1-200501040-00008
pubmed: 15630106
pmcid: 3722605
Sen A (2008) Recurrent cystitis in non-pregnant women. BMJ Clin Evid 07:801
Sessa R, Di Pietro M, Filardo S, Bressan A, Rosa L, Cutone A, Frioni A, Berlutti F, Paesano R, Valenti P (2017) Effect of bovine lactoferrin on Chlamydia trachomatis infection and inflammation. Biochem Cell Biol 95(1):34–40. https://doi.org/10.1139/bcb-2016-0049
doi: 10.1139/bcb-2016-0049
pubmed: 28094551
Singh PK, Parsek MR, Greenberg EP, Welsh MJ (2002) A component of innate immunity prevents bacterial biofilm development. Nature 417(6888):552–555. https://doi.org/10.1038/417552a
doi: 10.1038/417552a
pubmed: 12037568
Soto SM, Smithson A, Martinez JA, Horcajada JP, Mensa J, Vila J (2007) Biofilm formation in uropathogenic Escherichia coli strains: relationship with prostatitis, urovirulence factors and anti-microbial resistance. J Urol 177:365–368. https://doi.org/10.1016/j.juro.2006.08.081
doi: 10.1016/j.juro.2006.08.081
pubmed: 17162092
Subashchandrabose S, Mobley HL (2015) Back to the metal age: battle for metals at the host-pathogen interface during urinary tract infection. Metallomics 7(6):935–942. https://doi.org/10.1039/c4mt00329b
doi: 10.1039/c4mt00329b
pubmed: 25677827
Suzuki YA, Lopez V, Lönnerdal B (2005) Mammalian lactoferrin receptors: Structure and function. Cell Mol Life Sci 62:2560–2575. https://doi.org/10.1007/s00018-005-5371-1
doi: 10.1007/s00018-005-5371-1
pubmed: 16261254
Suzuki YA, Wong H, Ashida KY, Schryvers AB, Loönnerdal B (2008) The N1 domain of human lactoferrin is required for internalization by caco-2 cells and targeting to the nucleus. Biochemistry 47:10915–10920. https://doi.org/10.1021/bi8012164
doi: 10.1021/bi8012164
pubmed: 18785755
U.S. FDA (2014) GRN 000465 cow’s milk-derived lactoferrin; Morinaga Milk Industry Co., Ltd.: Tokyo, Japan; U.S. Food and Drug Administration (U.S. FDA), Center for Food Safety & Applied Nutrition (CFSAN), Office of Food Additive Safety: Silver Spring, MD, USA. http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=465 . Accessed 06 Apr 2022.
Valenti P, Antonini G (2005) Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 62:2576–2587. https://doi.org/10.1007/s00018-005-5372-0
doi: 10.1007/s00018-005-5372-0
pubmed: 16261253
Valenti P, Frioni A, Rossi A, Ranucci S, De Fino I, Cutone A, Rosa L, Bragonzi A, Berlutti F (2017) Aerosolized bovine lactoferrin reduces neutrophils and pro-inflammatory cytokines in mouse models of Pseudomonas aeruginosa lung infections. Biochem Cell Biol 95(1):41–47. https://doi.org/10.1139/bcb-2016-0050
doi: 10.1139/bcb-2016-0050
pubmed: 28129511
Vega-Bautista A, de la Garza M, Carrero JC, Campos-Rodríguez R, Godínez-Victoria M, Drago-Serrano ME (2019) The impact of lactoferrin on the growth of intestinal inhabitant bacteria. Int J Mol Sci 20:4707. https://doi.org/10.3390/ijms20194707
doi: 10.3390/ijms20194707
pubmed: 31547574
pmcid: 6801499
WHO Regional Office for Europe/European Centre for Disease Prevention and Control (2022) Antimicrobial resistance surveillance in Europe 2022–2020 data. Copenhagen: WHO Regional Office for Europe. https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data . Accessed 06 Apr 2022